Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

OBJECTIVE: The approved use of onabotulinumtoxinA for prophylaxis of headaches in patients with chronic migraine (CM) involves treatment every 12 weeks. It is currently unknown whether patients who fail to respond to the first onabotulinumtoxinA treatment cycle will respond to subsequent treatment c...

Descripción completa

Detalles Bibliográficos
Autores principales: Silberstein, Stephen D, Dodick, David W, Aurora, Sheena K, Diener, Hans-Christoph, DeGryse, Ronald E, Lipton, Richard B, Turkel, Catherine C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Migraine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552933/
https://www.ncbi.nlm.nih.gov/pubmed/25500317
http://dx.doi.org/10.1136/jnnp-2013-307149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552933/
https://www.ncbi.nlm.nih.gov/pubmed/25500317
http://dx.doi.org/10.1136/jnnp-2013-307149

Ejemplares similares